1. Brazil Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Biomm SA

Biomm SA

6.05
BRL
-0.13
(-2.10%)
0.18EPS
27.47P/E
848.49MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.03
0.17
0.9
1.49
1.39
1.38
1.14
2.08
2.86
Basic EPS, GAAP
-0.5
-0.37
0.24
-1.34
-1.07
-0.94
-1.08
-1.09
-1.11
-1.22
-0.94
-0.61
-0.05
0.23
Free Cash Flow per Basic Share
-2.12
-1.17
-1.4
-2.97
-1.69
-1.04
-1.66
-1.53
-1.41
-0.91
-0.94
-0.89
-1.03
-0.75
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.27
3.12
3.35
1.92
1.52
2.07
2.37
2.65
1.54
1.84
1.3
2.01
2.29
2.38
Tangible Book Value per Share
2.75
2.33
2.53
1.06
0.76
1.48
1.39
1.84
0.77
1.28
0.85
1.66
1.83
1.89
Basic Weighted Avg Shares
20
34
34
34
36
45
52
65
72
76
86
126
129
134
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
2
9
59
107
105
118
143
269
384
Operating Margin (%)
- -
- -
- -
- -
-34,389.32
-2,341.89
-588.22
-94.49
-61.3
-82.17
-61.04
-56.53
-1.78
10.61
Depreciation Expense
- -
- -
- -
- -
- -
2
5
10
12
12
11
12
9
11
Net Income, GAAP
-10
-13
8
-46
-38
-43
-56
-71
-80
-93
-81
-77
-7
30
Effective Tax Rate (%)
- -
- -
46.98
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15.38
Profit Margin (%)
- -
- -
- -
- -
-37,017.48
-2,717.88
-624.02
-120.62
-74.95
-88.19
-68.65
-54.05
-2.48
7.89
Working Capital
85
104
117
32
21
69
87
135
63
91
44
153
155
130
LT Debt
15
62
82
113
135
131
143
145
134
121
106
77
51
35
Total Equity
109
107
115
66
59
106
154
191
112
159
123
263
314
325
Return on Invested Capital (%)
- -
- -
4.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.64
Return on Capital (%)
- -
- -
6.05
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.88
Return on Common Equity (%)
- -
-11.77
7.45
-50.38
-60.89
-51.47
-42.99
-41.02
-52.97
-68.39
-57.54
-40.05
-2.32
10.77

Capital Structure

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
46
54
73
LT Borrowings
51
50
35
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
137
137
137
Market Capitalization
965
1,037
848

Working Capital

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
281
322
367
Cash, Cash Equivalents & STI
43
31
10
Accounts Receivable, Net
109
81
66
Inventories
97
183
253
Total Current Liabilities
126
182
237
Payables & Accruals
- -
- -
- -
ST Debt
46
54
73
Deferred Revenue
- -
- -
- -

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.68%
22.24%
19.3%
Free Cash Flow
19.09%
8.89%
19.22%
Net Income, GAAP
-67.73%
-15.95%
-91.34%
Sales/Revenue/Turnover
- -
40.51%
88.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39
32
32
40
143
2025
40
27
36
167
269
2026
92
89
- -
- -
- -

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.15
-0.14
-0.12
-0.2
-0.61
2025
-0.1
-0.11
-0.08
0.21
-0.05
2026
0.07
0.01
- -
- -
- -

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Heraldo Carvalho Marchezini
Full Time Employees
130
Sector
Health technology
Industry
Pharmaceuticals: major
Address
705 – Lagoa dos Ingleses São Paulo MG Brazil 34018-000
IPO Date
Sep 5, 2002
Website
biomm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Biomm S.A. (BIOM3.SA) is a biotechnology company focused on the development, manufacturing, and commercialization of high-value biological products, including biosimilars, biopharmaceuticals, and innovative therapies for chronic diseases. The company offers a portfolio of products such as recombinant human insulin and its analogs (e.g., glargine), monoclonal antibodies for oncology and autoimmune conditions, erythropoietins, and other complex biologics; it also provides contract development and manufacturing organization (CDMO) services for third-party biopharmaceutical production. Biomm operates primarily in Brazil with expanding presence in Latin America and select international markets, targeting public health systems, private healthcare providers, and global pharmaceutical partners; headquartered in Nova Lima, Minas Gerais, Brazil, the company was founded in 2012. In recent developments, Biomm completed a significant capital increase through a public offering in 2024, bolstering its expansion plans, and announced a strategic partnership with a leading global biotech firm for technology transfer in advanced gene therapies in early 2025. The company launched its first domestically produced biosimilar insulin glargine in Brazil in late 2024, marking a milestone in reducing import dependency for diabetes treatments, and acquired a complementary CDMO facility to enhance production capacity for monoclonal antibodies. These initiatives reflect Biomm's shift toward greater self-sufficiency in complex biologics manufacturing and entry into emerging segments like cell and gene therapies.